Publicaciones en las que colabora con Pilar Alejandra Saiz Martínez (31)

2024

  1. Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation

    Schizophrenia Bulletin, Vol. 50, Núm. 2, pp. 327-338

2023

  1. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    Psychiatry Research, Vol. 323

  2. Structural covariance predictors of clinical improvement at 2-year follow-up in first-episode psychosis

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 120

  3. The polygenic basis of relapse after a first episode of schizophrenia

    European Neuropsychopharmacology, Vol. 75, pp. 80-92

  4. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2022

  1. A replication study of JTC bias, genetic liability for psychosis and delusional ideation

    Psychological Medicine, Vol. 52, Núm. 9, pp. 1777-1783

  2. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway

    Psychological Medicine, Vol. 52, Núm. 10, pp. 1910-1922

  3. Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 113

  4. Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients

    Schizophrenia, Vol. 8, Núm. 1

  5. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    European Neuropsychopharmacology, Vol. 63, pp. 47-59

  6. The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study

    European Neuropsychopharmacology, Vol. 57, pp. 105-117

2021

  1. A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

    Molecular Psychiatry, Vol. 26, Núm. 8, pp. 4529-4543

  3. Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    European psychiatry : the journal of the Association of European Psychiatrists, Vol. 64, Núm. 1, pp. e25

2020

  1. Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum

    Epidemiology and Psychiatric Sciences

  2. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort

    Acta Psychiatrica Scandinavica, Vol. 141, Núm. 6, pp. 541-552

  3. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529

  4. Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study

    Psychological Medicine, Vol. 50, Núm. 11, pp. 1884-1897

2019

  1. Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis

    European Child and Adolescent Psychiatry, Vol. 28, Núm. 10, pp. 1395-1405

  2. Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study

    Schizophrenia bulletin, Vol. 45, Núm. 5, pp. 960-965